Cardiomyopathy secondary prevention: Difference between revisions
No edit summary |
Lina Yaqoub (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation. | |||
==References== | ==References== | ||
| Line 15: | Line 17: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
{{CALISKAN, K. , SZILI‐TOROK, T. , THEUNS, D. A., KARDOS, A. , GELEIJNSE, M. L., BALK, A. H., VAN DOMBURG, R. T., JORDAENS, L. and SIMOONS, M. L. (2011), Indications and Outcome of Implantable Cardioverter‐Defibrillators for Primary and Secondary Prophy}} | |||
Revision as of 18:02, 16 December 2018
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy secondary prevention |
|
Risk calculators and risk factors for Cardiomyopathy secondary prevention |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation.
References
Template:WH Template:WS Template:CALISKAN, K. , SZILI‐TOROK, T. , THEUNS, D. A., KARDOS, A. , GELEIJNSE, M. L., BALK, A. H., VAN DOMBURG, R. T., JORDAENS, L. and SIMOONS, M. L. (2011), Indications and Outcome of Implantable Cardioverter‐Defibrillators for Primary and Secondary Prophy